Drug intelligence / Profile preview

denlorlatinib

Development stage: Unknown
Lead developer: Nanjing Zaiming Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Denlorlatinib (formerly SY-5007) is a potent, selective, and brain-penetrant small-molecule tyrosine kinase inhibitor (TKI) targeting Anaplastic Lymphoma Kinase (ALK) and ROS proto-oncogene 1 (ROS1). Developed by Nanjing Zaiming Pharmaceutical, a subsidiary of Simcere, the drug is designed to overcome resistance mutations common in earlier-generation ALK inhibitors and features high blood-brain barrier permeability to effectively treat central nervous system (CNS) metastases. It is currently in Phase 3 clinical development for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC) and is also being investigated for ROS1-positive advanced solid tumors.

Other names: SY5007SY-5007SY 5007

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on denlorlatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on denlorlatinib.

Explore the full profile